Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

A Study to Assess a PI3K´Inhibitor (IOA-244) in Patients With Metastatic Cancers

NCT ID: NCT04328844 Phase: PHASE1 Sponsor: iOnctura Status: Active Not Recruiting

SUMMARY

The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)

KEY ELIGIBILITY CRITERIA

- 1. e18 years of age inclusive, at the time of signing the informed consent.
- 2. Capable of giving signed informed consent, which includes compliance with the requirements of this protocol.
- 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. For patients with NHL, ECOG 2 will be allowed.
- 4. Patients with histologically or cytologically confirmed advanced or metastatic malignancies (including histologically confirmed, unresectable Stage III or IV melanoma); see following details for each malignancy:
- For Patients with cutaneous and mucosal melanoma:
- 1. Baseline lactate dehydrogenase levels are available.
- 2. Disease progression is confirmed and they are eligible for second- or third-line treatment:
- * After first-line treatment and progression on approved programmed cell death-1 (PD-1) or cytotoxic T lymphocyte antigen-4 (CTLA-4) or combination of PD-1 and CTLA-4-pathway targeted agent.
- * After second-line treatment and progression on prior BRAF V600 mutation targeted agent followed by PD-1 or CTLA-4-pathway targeted agent (Note: There is no mandatory sequence of these approved treatments).
- 3. No clinically significant tumour-related symptoms.

Total sites: 3 | 0 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT04328844) and public sources. Generated by FindMyCure.ai.